Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Cullinan Therapeutics Inc.
Headquarters: Cambridge, MA, United States of America
Website: http://www.cullinanoncology.c...
Year Founded: 2016
Status: Public
Industry Sector: HealthTechnology
CEO: Nadim Ahmed
Number Of Employees: 111
Enterprise Value: $258,104,780
PE Ratio: -2.84
Exchange/Ticker 1: NASDAQ:CGEM
Exchange/Ticker 2: N/A
Latest Market Cap: $521,934,208
BioCentury | Feb 5, 2025
Product Development
Biotechs make inroads to precision medicine, solving long-standing problems
70% of new precision medicines approved by FDA in past three years were not sponsored by major pharmas
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New I&I indications take center stage
Inflammation and immunology readouts to define new priority indications, modality opportunities in immune reset
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: Bispecifics poised to enter new era
Decade after first approval, bispecifics on the precipice of going mainstream
BioCentury | Nov 21, 2024
Management Tracks
Boshoff to succeed Dolsten as Pfizer CSO
Plus: Hwang joins Metaphore, Flagship and updates from FDA, MHRA, ArrePath, ABT, Unnatural, Thryv and more
BioCentury | Nov 6, 2024
Management Tracks
SOBI to propose David Meek as chair
Plus: Seaport hires Lauren White as CFO, and updates from Tarsus and Takeda
BioCentury | Oct 22, 2024
Product Development
Newco trend watch: Clusters of launches point to areas undergoing derisking
Oligo delivery to the kidney, and two emerging use cases for T cell engagers, each get newcos; most with mega-
BioCentury | Sep 10, 2024
Emerging Company Profile
Candid: Bispecifics for autoimmunity, leveraging Chinese oncology innovation
Ken Song’s post-RayzeBio venture pulled together two licensing deals, an M&A transaction and three financings totaling $370M
BioCentury | Apr 30, 2024
Product Development
Clinical report: Academic trials signal autoimmune opportunities for T cell engagers
Plus: Results from Lilly’s Verzenio, antibody-drug conjugate Enhertu, and programs from Newron and Annovis
BioCentury | Apr 19, 2024
Finance
Public equity report: Depression data drive Intra-Cellular’s $500M raise
Plus public offerings for Biohaven and TScan, and PIPEs for Cullinan and Zura
BioCentury | Apr 17, 2024
Product Development
Cullinan adds T cell engagers to modality migration from cancer to autoimmunity
Cullinan raises a $280 million PIPE to develop CLN-978 for lupus
Items per page:
1 - 10 of 10